CoChat

Insulin Analogs Versus Human Insulin in the Treatment of Patients With Diabetic Ketoacidosis

Open access

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To compare the safety and efficacy of insulin analogs and human insulins both during acute intravenous treatment and during the transition to subcutaneous insulin in patients with diabetic ketoacidosis (DKA). RESEARCH DESIGN AND METHODS: In a controlled multicenter and open-label trial, we randomly assigned patients with DKA to receive intravenous treatment with regular or glulisine insulin until resolution of DKA. After resolution of ketoacidosis, patients treated with intravenous regular insulin were transitioned to subcutaneous NPH and regular insulin twice daily (n = 34). Patients treated with intravenous glulisine insulin were transitioned to subcutaneous glargine once daily and glulisine before meals (n = 34). RESULTS: There were no differences in the mean duration of treatment or in the amount of insulin infusion until resolution of DKA between intravenous treatment with regular and glulisine insulin. After transition to subcutaneous insulin, there were no differences in mean daily blood glucose levels, but patients treated with NPH and regular insulin had a higher rate of hypoglycemia (blood glucose <70 mg/dl). Fourteen patients (41%) treated with NPH and regular insulin had 26 episodes of hypoglycemia and 5 patients (15%) in the glargine and glulisine group had 8 episodes of hypoglycemia (P = 0.03). CONCLUSIONS: Regular and glulisine insulin are equally effective during the acute treatment of DKA. A transition to subcutaneous glargine and glulisine after resolution of DKA resulted in similar glycemic control but in a lower rate of hypoglycemia than with NPH and regular insulin. Thus, a basal bolus regimen with glargine and glulisine is safer and should be preferred over NPH and regular insulin after the resolution of DKA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc09-0169

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Changes in metabolic profile in patients with DKA treated with intravenous glulisine (○) and regular insulin (●). To convert the values for glucose from milligrams per deciliter to millimoles per liter, multiply by 0.05551. A: glucose; B: pH; C: bicarbonate; D: anion gap.
Figure 1 Changes in metabolic profile in patients with DKA treated with intravenous glulisine (○) and regular insulin (●). To convert the values for glucose from milligrams per deciliter to millimoles per liter, multiply by 0.05551. A: glucose; B: pH; C: bicarbonate; D: anion gap.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 123

Metadata

Authors
Umpierrez, G. E., Jones, S., Smiley, D., Mulligan, P., Keyler, T., Temponi, A., Semakula, C., Umpierrez, D., Peng, L., Cerón, M., & Robalino, G.
Affiliations
  • Emory University (US)
  • University of Minnesota (US)
  • Department of Medicine, Emory University School of Medicine, Atlanta, Georgia;
Corresponding author
Umpierrez, Guillermo E.
Venue
Diabetes Care
Published
2009-04-14
Volume
32
Issue
7
Pages
1164-1169
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2123006117
Cited by
120
References
25
Citations by year
2026: 1 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 9 · 2021: 4 · 2020: 12 · 2019: 4 · 2018: 11 · 2017: 9 · 2016: 9 · 2015: 12 · 2014: 7 · 2013: 7 · 2012: 12
FWCI
6.07
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • American Diabetes Association (7-03-CR-35)
  • Sanofi
  • National Institutes of Health (UL1TR000454)
  • National Institute of Diabetes and Digestive and Kidney Diseases (U01DK074556)
  • National Center for Research Resources (M01-RR00039, M01RR000039)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
Keywords
diabetic ketoacidosis, insulin analogues, regular insulin, NPH insulin, insulin glargine, multiple daily insulin injections, hypoglycemia, glycemic control, intravenous insulin therapy
MeSH terms
Adult, Blood Glucose, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin, Isophane, Male, Middle Aged, Patient Compliance, Recombinant Proteins, Diabetic Ketoacidosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Insulin Analogs Versus Human Insulin in the Treatment of Patients With Diabetic Ketoacidosis. https://app.cochat.ai/papers/10.2337/dc09-0169
The paper
Umpierrez, G. E., Jones, S., Smiley, D., Mulligan, P., Keyler, T., Temponi, A., Semakula, C., Umpierrez, D., Peng, L., Cerón, M., & Robalino, G. (2009). Insulin Analogs Versus Human Insulin in the Treatment of Patients With Diabetic Ketoacidosis. Diabetes Care. https://doi.org/10.2337/dc09-0169

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.